石见穿多糖对肝腹水H22荷瘤小鼠的作用及可能机制
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

国家自然科学基金(81960549)


Effect of PSSC on tumor bearing mice(H22) in vivo and in vitro and JAK / STAT signaling pathway
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨石见穿多糖(PSSC)对肝腹水H22荷瘤小鼠的作用效果及可能机制。方法 选取BALB/c小鼠80只,建立H22荷瘤小鼠模型,随机分为5组:对照组、环磷酰胺组(CTX,20 mg/kg)、PSSC组(20、40和120 mg/kg),每组16只。观察各组小鼠腹部周长、体重、生存率及生存时间;采用脾淋巴细胞转化试验检测T、B淋巴细胞增殖情况;E-玫瑰花结实验观察T细胞的免疫功能状态;ELISA法检测血清和腹水中白介素2(IL-2)、γ-干扰素(IFN-γ)、肿瘤坏死因子-α(TNF-α)、血管内皮生长因子(VEGF)含量;TUNEL法检测H22细胞凋亡;Caspase比色法测定Caspase-3和Caspase-8酶活性;Western blot法检测Janus激酶1(Jak1)、信号传导和转录激活因子-3(Stat3)、Bcl2-相关X蛋白(Bax),B淋巴细胞瘤-2(Bcl-2)蛋白表达。结果 与对照组相比,PSSC组的腹部周长和体重显著下降,而存活率和存活时间呈剂量依赖性增加;与CTX组相比,PSSC 40、120 mg/kg组腹部周长和体重下降,而存活率和存活时间升高(均P<0.05)。与对照组相比,PSSC组小鼠SI及EtRFC随PSSC治疗剂量的增加而增加;与CTX组相比,PSSC 120 mg/kg组SI及EtRFC百分比升高(均P<0.05)。ELISA检测结果,与对照组相比,PSSC组H22肿瘤小鼠血清和腹水中的IL-2、IFN-γ和TNF-α水平呈剂量依赖性增加,而VEGF表达降低;与CTX组相比,PSSC 120 mg/kg组小鼠血清和腹水中的IL-2、IFN-γ和TNF-α表达升高,而VEGF表达下降(均P<0.05)。TUNEL实验显示,与对照组相比,PSSC呈剂量依赖性增加H22细胞凋亡数量;与对照组相比,随着PSSC浓度的增加,Caspase-3和Caspase-8表达上升(P<0.05);Western blot检测结果,PSSC组Jak1、Stat3和Bcl-2蛋白表达较对照组降低,而Bax/Bcl-2比值上升。结论 石见穿多糖对H22 荷瘤小鼠具有一定的抗肿瘤作用,其机制可能与免疫调节与抗凋亡作用有关。

    Abstract:

    Objective To explore the effect and possible mechanism of PSSC on H22 Tumor bearing mice with hepatoma ascites. Methods Eighty BALB/ C mice were selected to establish H22 tumor-bearing mice model, and randomly divided into 5 groups: control group, cyclophosphamide group(CTX, 20 mg/kg), PSSC group(20, 40 and 120 mg/kg), with 16 mice in each group. Abdominal circumference, weight, survival rate and survival time of mice in each group were observed. T and B lymphocyte proliferation were detected by spleen lymphocyte transformation test. T cell immune function was observed by E- rosette experiment. The concentrations of IL-2, γ- interferon, TNF-α and VEGF in serum and ascites were detected by ELISA. Apoptosis of H22 cells was detected by TUNEL assay. The activities of Caspase-3 and Caspase-8 were determined by Caspase- colorimetry. The expressions of Janus kinase 1(Jak1), signaling and transcription activator -3(Stat3), Bcl2- related X protein(Bax) and B lymphocytoma -2(Bcl-2) were detected by Western blot. Results Compared with the control group, the abdominal circumference and body weight of PSSC group decreased significantly, while the survival rate and survival time increased in a dose-dependent manner; Compared with CTX group, PSSC 40 and 120mg/kg groups decreased abdominal circumference and body weight, but increased survival rate and survival time(P<0.05). Compared with the control group, SI and EtRFC in PSSC group increased with the increase of PSSC treatment dose; Compared with CTX group, the percentage of SI and EtRFC in PSSC 120mg/kg group increased(P<0.05). Compared with the control group, the levels of IL-2, IFN-γ and TNF-α in serum and ascites of H22 Tumor Mice in PSSC group increased in a dose-dependent manner, while the expression of VEGF decreased. Compared with CTX group, the expressions of IL-2, IFN-γ and TNF-α in serum and ascites of mice in PSSC 120 mg/kg group were increased, while the expression of VEGF was decreased. TUNEL showed that PSSC increased the apoptosis of H22 cells in a dose-dependent manner compared with the control group. Compared with the control group, the expression of Caspase-3 and caspase-8 increased with the increase of PSSC concentration. The results of westerblot showed that the expression of Jak1, STAT3 and bcl-2 protein in PSSC group was lower than that in control group, while the ratio of Bax/Bcl-2 was higher. Conclusion PSSC has anti-tumor effect on H22 Tumor bearing mice, and its mechanism may be related to immune regulation and anti apoptosis.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-07-20
您是第位访问者
网站版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司